ABEONA THERAPEUT. DL-01 Market Cap ($256.10 Million)
Market Cap & Net Worth: ABEONA THERAPEUT. DL-01 (PCJ)
ABEONA THERAPEUT. DL-01 market cap. ABEONA THERAPEUT. DL-01 (F:PCJ) has a market capitalization of $256.10 Million (€219.05 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #15314 globally and #1499 in its home market, demonstrating a -0.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABEONA THERAPEUT. DL-01's stock price €3.85 by its total outstanding shares 56882523 (56.88 Million). Also see ABEONA THERAPEUT. DL-01 (PCJ) cash conversion ratio for how efficiently the company converts equity into cash flow.
ABEONA THERAPEUT. DL-01 Market Cap History (2015–2026)
ABEONA THERAPEUT. DL-01 market cap history from 2015 to 2026. Data shows growth from $210.08 Million to $256.10 Million (0.66% CAGR). Check PCJ stock price for real-time trading data and today's change.
ABEONA THERAPEUT. DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABEONA THERAPEUT. DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ABEONA THERAPEUT. DL-01 (PCJ) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
53.25x
ABEONA THERAPEUT. DL-01's market cap is 53.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.35x
ABEONA THERAPEUT. DL-01's market cap is 4.35 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $17.30 Million | $3.00 Million | -$84.94 Million | 5.77x | N/A |
| 2022 | $171.57 Million | $1.41 Million | -$39.70 Million | 121.34x | N/A |
| 2023 | $301.25 Million | $3.50 Million | -$54.19 Million | 86.07x | N/A |
| 2025 | $309.90 Million | $5.82 Million | $71.18 Million | 53.25x | 4.35x |
Competitor Companies of PCJ by Market Capitalization
Companies near ABEONA THERAPEUT. DL-01 in the global market cap rankings as of November 4, 2026. Also see ABEONA THERAPEUT. DL-01 total assets for a full breakdown of the balance sheet.
Key companies related to ABEONA THERAPEUT. DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ABEONA THERAPEUT. DL-01 (2015–2026)
Market capitalization of ABEONA THERAPEUT. DL-01 from 2015 to today. Between 2015 and today, ABEONA THERAPEUT. DL-01's market cap moved from $210.08 Million to $ 256.10 Million, with a yearly change of 0.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €256.10 Million | -17.36% |
| 2025 | €309.90 Million | -11.24% |
| 2024 | €349.13 Million | +15.89% |
| 2023 | €301.25 Million | +75.58% |
| 2022 | €171.57 Million | +891.54% |
| 2021 | €17.30 Million | -78.84% |
| 2020 | €81.76 Million | -59.02% |
| 2019 | €199.50 Million | -47.28% |
| 2018 | €378.39 Million | -57.30% |
| 2017 | €886.07 Million | +190.98% |
| 2016 | €304.51 Million | +44.95% |
| 2015 | €210.08 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ABEONA THERAPEUT. DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $256.10 Million USD |
| MoneyControl | $256.10 Million USD |
| MarketWatch | $256.10 Million USD |
| marketcap.company | $256.10 Million USD |
| Reuters | $256.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more